KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Blood · 2025-Sep-11 · PMID 40198878

Panel OS_in_patients_overall提取完成待 EXE 对齐验证

Overall survival

Figure 3. OS in patients overall. ∗HR based on stratified Cox proportional hazards model; † P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; § P value based on unstratified log-rank test. Clb, chlorambucil.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.91
质量通过是
预期曲线3
实际曲线3
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证32026-07-23T16:28:00+00:00